Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in type 2 diabetes mellitus with moderate renal impairment
2016-004889-26Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoints: Change in HbA1c for dose 1 versus placebo and Change in HbA1c for dose 2 versus placebo. Started Jul 2017; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-004889-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004889-26.